Using Targeted Virotherapy to Treat a Resistant Ewing Sarcoma Model: From the Bedside to the Bench and Back
Figure 5
VSVΔM51 shows tumor-specific replication after its systemic delivery in nude mice harboring subcutaneous and lung tumors. In one group (a), a solid tumor mass developed in the hind-foot region a week after the subcutaneous inoculation of EWS cells. No tumor nodules were noted on gross inspection of the lungs (a). The second cohort of mice (d) was inoculated with EWS both subcutaneously and intravenously. Numerous tumor nodules were noted bilaterally on gross inspection of the lungs (b). After tumor growth in both groups, VSVΔM51-Luc was administered intravenously. At 72 h after treatment, In vivo Imaging System (IVIS) was used to assess viral replication in live animals. The luciferase signal is noted only at the tumor site in both groups ((c)-(d)).
